S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

$44.21
+0.37 (+0.84 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$43.67
Now: $44.21
$44.28
50-Day Range
$42.32
MA: $44.22
$45.46
52-Week Range
$35.30
Now: $44.21
$46.22
Volume2.22 million shs
Average Volume4.23 million shs
Market Capitalization$116.00 billion
P/E Ratio25.55
Dividend Yield2.01%
Beta0.47
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-3749-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.09 billion
Cash Flow$3.26 per share
Book Value$5.54 per share

Profitability

Net Income$2.16 billion

Miscellaneous

Employees64,400
Outstanding Shares2,623,764,000
Market Cap$116.00 billion
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.


AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Friday, February 15th. Shareholders of record on Friday, March 1st will be given a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date of this dividend is Thursday, February 28th. This is a positive change from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) announced its quarterly earnings data on Thursday, July, 25th. The company reported $0.73 EPS for the quarter, beating the Zacks' consensus estimate of $0.30 by $0.43. The company earned $5.72 billion during the quarter, compared to analyst estimates of $5.57 billion. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The business's quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.69 earnings per share. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.54.

What price target have analysts set for AZN?

18 Wall Street analysts have issued 1-year price targets for AstraZeneca's stock. Their forecasts range from $40.73 to $50.00. On average, they expect AstraZeneca's share price to reach $46.12 in the next year. This suggests a possible upside of 4.3% from the stock's current price. View Analyst Price Targets for AstraZeneca.

What is the consensus analysts' recommendation for AstraZeneca?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News stories about AZN stock have trended extremely negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for AstraZeneca.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include AT&T (T), Pfizer (PFE), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Micron Technology (MU), Intel (INTC) and General Electric (GE).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:
  • Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Park National Corp OH (0.01%), Crossmark Global Holdings Inc. (0.00%), Gradient Investments LLC (0.00%), TIAA FSB (0.00%), Town & Country Bank & Trust CO dba First Bankers Trust CO (0.00%) and Pacer Advisors Inc. (0.00%). View Institutional Ownership Trends for AstraZeneca.

Which major investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gradient Investments LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, TIAA FSB, Valeo Financial Advisors LLC and SeaCrest Wealth Management LLC. View Insider Buying and Selling for AstraZeneca.

Which major investors are buying AstraZeneca stock?

AZN stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, Fox Run Management L.L.C., Pacer Advisors Inc., Henry James International Management Inc., RB Capital Management LLC and Private Trust Co. NA. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $44.21.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $116.00 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

What is AstraZeneca's official website?

The official website for AstraZeneca is http://www.astrazeneca.com/.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (NYSE AZN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  712 (Vote Outperform)
Underperform Votes:  1,112 (Vote Underperform)
Total Votes:  1,824
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Dividend Yield

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel